Skin care compositions

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to cosmetology and dermatology and represents a skin care composition applicable for local skin application, wherein the above composition contains salicylic acid or its salt in a combination with glycyrrhizic acid, or its salt or its derivative, cetylhydroxyproline palmitamide, lactic acid or its salt, bisabolol and niacinamide.

EFFECT: invention provides extending the range of effective skin care agents.

41 cl, 11 ex, 11 tbl

 

The present invention relates to compositions for skin care, in particular to compositions effective in the treatment of acne vulgaris, and to methods of treatment of the skin, which include the application of such compositions.

Ordinary (youth) acne or acne are chronic inflammatory condition pilosebaceous complexes of the skin, which often especially common in adolescence. This status basically causes the formation on the skin, blackheads (comedones), red papules, pustules and sometimes cysts. They spoil the appearance and, in addition, if left untreated, acne can lead to scarring of the skin. It is believed that the main causes of acne are the increase in the formation of sebum, an increased level of propionibacteria (P. acne), blockade pilosebaceous ducts and inflammatory processes.

It is known that salicylic acid is effective in the treatment of acne. She is a local keratolytic agent, which acts by dissolving the intercellular binding agent, which binds epithelial cells together. Salicylic acid is used in a variety of non-prescription formulations for the treatment of acne.

To improve the effectiveness of local treatment of acne it is advisable to add to salicylic acid, one or more adjusting�x substances to suppress sometimes observed inflammatory effects such as local peeling of the skin and discomfort, including burning and redness of the skin.

It has surprisingly been found that compositions for skin care containing salicylic acid and at least two or more appropriately selected active ingredient, possess high therapeutic efficacy in the treatment of acne. Such compositions for skin care can treat acne and reduce visible redness.

Thus, according to the first aspect of the present invention proposed composition for skin care, suitable for topical application to the skin, wherein the composition comprises salicylic acid or its salt in combination of at least two active ingredients selected from the group which consists of:

- lactic acid or its salt;

- glycyrrhizic acid or its salt, or its derivative;

- bisabolol;

- palmitate of catalytically;

- allantoin;

- Niacinamide; and

- extract fireweed (epilobium canadian, Epilobium angustifolium).

It was shown that this treatment provides advantages in comparison with existing methods in the treatment of acne, in particular, especially from the perspective of cutaneous tolerability in the treatment of acne. This treatment may have the effect of reducing the degree of acne and therefore any associated priznaki� or scars; in addition, can be reduced skin irritation. Other signs of these advantages are the reduction of inflammation of affected skin and/or softening effect. The synergies between the selected ingredients of the composition can reduce the amount of each separate ingredient.

Salicylic acid is preferably incorporated in the composition according to the present invention in the form of the free acid. However, the pH of the composition can, and usually is, such that salicylic acid exists in the composition in a dissociated form. Since the composition can also contain cations as counterions, it is possible to prevent the presence of salicylic acid in the form of salt. Alternatively, salicylic acid can be directly included in the composition in the form of salts, for example, in the form of a salt of a group I metal, such as sodium salicylate. In the present description, unless the context indicates otherwise, any and all references to salicylic acid should be considered as containing links to the acid and its dissociated forms and salts.

The concentration of salicylic acid in the composition according to the present invention is preferably at least 0.01 wt.%, preferably, at least 0.1 wt.%, most preferably at least 0.5 wt.% and OS�Benno preferably at least 1 wt.%. The concentration of salicylic acid is preferably less than 10 wt.%, preferably less than 5 wt.%, most preferably less than 4 wt.% and particularly preferably less than 3 wt.%. Consequently, the concentration of salicylic acid can be in the range of from 0.01 wt.% up to 10 wt.%, preferably from 0.1 wt.% up to 5 wt.%, most preferably from 0.5 wt.% up to 4 wt.% and especially preferably from 1 wt.% to 3 wt.%. Especially preferred concentration of salicylic acid is 2 wt%.

The concentration of lactic acid or its salts, in case of their presence in the composition is at least 0.01 wt.%, preferably at least 0.1 wt.% and most preferably at least 1 wt.%; and less than 10 wt.%, preferably less than 5 wt.% and most preferably less than 3 wt.%.

The concentration of glycyrrhizic acid or its salt or derivative, in case of their presence in the composition is at least 0.01 wt.% and less than 2 wt.%, preferably less than 1 wt.% and most preferably less than 0.5 wt.%.

The concentration of bisabolol, when present in the composition is at least 0.001 wt.%, preferably, at least 0.01 wt.% and less than 1 wt.%, preferably less than 0.5 wt.%.

The concentration of palmated of catalytically, if p�estste in the composition, is at least 0.001 wt.%, preferably, at least 0.01 wt.% and less than 1 wt.%, preferably less than 0.5 wt.%.

The concentration of allantoin, in case of its presence in the composition is at least 0.01 wt.%, preferably, at least 0.1 wt.% and most preferably at least 0.2 wt.% and less than 5 wt.%, preferably less than 2 wt.% and most preferably less than 1 wt.%.

The concentration of Niacinamide, in case of its presence in the composition is at least 0.01 wt.%, preferably, at least 0.1 wt.% and most preferably at least 0.5 wt.%, and less than 10 wt.%, preferably less than 5 wt.%.

The concentration of extract of Epilobium angustifolium, in case of its presence in the composition is at least 0.01 wt.% and less than 5 wt.%, preferably less than 1 wt.% and most preferably less than 0.5 wt.%.

In a particularly preferred embodiment of the present invention proposed composition for skin care containing from 0.1 to 5 wt.% salicylic acid or its salts, in combination, at least two active ingredients selected from the group which consists of:

- 0.1 to 5 wt.% lactic acid or its salts;

- 0.01 to 1 wt.% glycyrrhizic acid or its salts;

is 0.001-1 wt.% of bisabolol;

is 0.001-1 wt.% palmated satellitosis�Lina;

- 0.1 to 2 wt.% allantoin;

- 0.1 to 5 wt.% Niacinamide;,

is 0.001-1 wt.% extract of Epilobium angustifolium.

In another particularly preferred embodiment of the present invention proposed composition for skin care containing from 1 to 3 wt.% salicylic acid or its salts in combination with at least two active ingredients selected from the group which consists of:

- 1-3 wt.% lactic acid or its salts;

is 0.01 - 0.5 wt.% glycyrrhizic acid or its salt, or a derivative

- 0.02 to 0.5 wt.% of bisabolol;

is 0.01 - 0.5 wt.% palpitated of catalytically;

- 0.2 to 1 wt.% allantoin;

- 0.5 to 5 wt.% Niacinamide;

is 0.01-0.5 wt.% extract of Epilobium angustifolium. This composition is preferably made in such a way that the pH value was in the range from 2.5 to 8.0, preferably from 3.0 to 7.0, and in particular from 3.5 to 6.0, for example, to a value of pH were 4.5 or 5.5.

The composition according to the present invention may contain one or more other active ingredients for topical application, which are used for skin care. Such active ingredients may include one or more of the following:

antimicrobial or antibacterial compounds, for example selected from the group comprising triclosan, neomycin, clindamycin, polymyxin, bacitracin benzoylperoxide, hydrogen peroxide, tetracycline, such as doxycycline or minocycline, sulfonamide drugs such as sulfacetamide, penicillins, cephalosporins such as cephalexin, and quinolones such as lomefloxacin, ofloxacin or trovafloxacin;

antiviral compounds, for example selected from the group comprising acyclovir, famivir and penciclovir;

antifungal compounds, for example selected from the group comprising famesol, clotrimazole, ketoconazole, econazole, fluconazole, calcium undecylenate and zinc, undecylenic acid, hydrochloride butenafine, ciclopiroxolamine, miconazole nitrate, nystatin, sulconazole and terbinafine hydrochloride;

anti-inflammatory compounds, for example: steroid means selected from the group which consists of hydrocortisone, the acetonide fluocinolone, halcinonide, propionate halobetasol, clobetasol propionate, and betamethasone dipropionate, valerate and betamethasone, and triamcinolone acetonide; and nonsteroidal anti-inflammatory agents selected from the group which consists of aspirin, ibuprofen, Ketoprofen, naproxen, aloe Vera gel, aloe extract, licorice extract, bulbous Buttercup or zinc.

Antihelminthic compounds, such as metronidazole.

The composition according to the present invention can be fabricated�to provide for multiple forms. However, the form of composition often represent water or oil lotion, a dispersion, an emulsion or a gel containing a surfactant. The emulsion may be an oil in water emulsion or an emulsion of water in oil.

The oil phase of the emulsions can contain, without limitation: (a) hydrocarbon oils such as paraffin or mineral oils; b) waxes such as beeswax or paraffin wax; c) natural oils such as sunflower oil, oil of apricot pits, oil oil of a tree or jojoba oil; d) silicone oils such as Dimethicone, cyclomethicone or acidimeter; (e) esters of fatty acids, such as isopropylpalmitate, isopropyl myristate, distilled, glyceridae and testosteronediet; (f) fatty alcohols, such as cetyl alcohol, stearyl alcohol and their mixture (for example, Cetearyl alcohol); (g) ethers of polypropylene glycol or polyethylene glycol, for example, butyl ether, PPG-14; or (h) mixtures thereof, for example, the wax mixture supplied to the market under the trade name Cutina firm Henkel.

Used emulsifiers can be any emulsifiers known in the art and used in emulsions or microemulsion of the type water - in-oil or oil-in-water. Known cosmetically acceptable emulsifiers may include: (a) sesquioleate, �what sesquioleate sorbitol, supplied for sale, for example, under the trade name Arlacel 83 (ICI), or polyglyceryl-2-sesquioleate; (b) ethoxylated esters of derivatives of natural oils such as polyethoxysiloxane ester hydrogenated castor oil supplied for sale, for example, under the trade name Arlacel 989 (ICI); (c) silicone emulsifiers such as silicone polyols, supplied for sale, for example, under the trade name Abil stock WS08 (Th. Goldschmidt AG); (d) anionic emulsifiers such as salts of fatty acids, e.g. potassium stearate, sulfates of fatty acids, for example, cetostearyl sodium supplied for sale, for example, under the trade name Dehydag (Henkel); (e) ethoxylated fatty alcohols, for example, emulsifiers, supply for sale, for example, under the trade name Brij (ICI); (f) esters of sorbitol, for example, emulsifiers supplied for sale under the trade name Span (ICI); (g) ethoxylated esters of sorbitol, for example, emulsifiers supplied for sale under the trade name Tween (ICI); (h) esters of ethoxylated fatty acids such as ethoxylated stearates, glycerylmonostearate, for example, emulsifiers supplied for sale under the trade name Myrj (ICI); (i) ethoxylated mono-, di - and triglycerides, for example, emulsifiers supplied� for sale under the trade name Labrafil (Alfa Chem.); (j) non-ionic self emulsifiable waxes, e.g., beeswax supplied for sale under the trade name Polawax (Croda); k) ethoxylated fatty acids, for example, emulsifiers supplied for sale under the trade name Tefose (Alfa Chem.) (1) esters of methylglucose, such as distearate the polyglycerol-3-methylglucose supplied for sale under the trade name Tegocare 450 (Degussa Goldschmidt); and (m) polyacrylamide emulsifying system, such as the cream-gel emulsifier under the trade name Sepigel 305 (Seppic), or (n) mixtures thereof.

Gels, proposed according to the present invention may be aqueous or nonaqueous. Preferred are aqueous gels. The gel usually contains a gelling agent, which imparts a gel of sufficient viscosity. Suitable gelling agents may constitute hydroxypropanoic or copolymer acryloyldimethyltaurate acid (or its salt), especially a copolymer of a specified monomer with another vinyl monomer.

The specified salt may be a salt of an alkali metal of group I, but preferably ammonium salt. Examples of suitable copolymer gelling agents include a copolymer of acryloyldimethyltaurate ammonium and vinylpyrrolidone, a copolymer of acryloyldimethyltaurate ammonium and beginat-25-methacrylate, a copolymer of acryloyldimethyltaurate ammonium and blame�formamide. The materials supplied by the company Clariant GmbH range of products under the trade name Aristoflex.

You can also use a variety of thickeners according to the nature of the liquid carrier and the desired viscosity. Preferred thickening agents which are water soluble or hydrophilic in nature, and their examples include polymers of acrylic acid, for example, polymers that are supplied for sale under the trade name Carbopol (B. F. Goodrich), modified cellulose, such as methylcellulose or hydroxyethylcellulose, supplied for sale under the trade name Natrosol (Hercules), alkylhalogenide supplied for sale under the trade name N-Hance, xanthan gum, cetyl alcohol and sodium chloride.

The amount of gelling agent and/or thickener in the composition is from 0.1 to 5 wt.%, preferably from 0.5 to 5 wt.% for each agent. In a typical case, the amount of gelling agent and/or thickener is less than 3 wt.%, for example, approximately 1 wt.% or about 2 wt.% for each agent.

The composition according to the present invention preferably has a viscosity of approximately 10,000 MPa"s to about 200000 MPa"s. the Viscosity can be measured with a viscometer Brookfield RVT equipped with T-shaped spindle type, with rotating soon�TEW 5 rpm, in for one minute.

In many cases, it is preferable that the composition contained helatoobrazovatel or chelating agent, or other substance capable of forming complexes or other interaction with metal ions present in the composition. Such substances can increase the stability of the composition and, in particular, may inhibit or prevent the decomposition of certain ingredients (e.g., flavors). Examples of helatoobrazovateli or complexing include ethylenediaminetetraacetic acid and its salts, preferably the dikalova and preferably the disodium salt.

In the case of solutions or dispersions, and gels these compositions usually contain a system of solvents or other continuous liquid phase. Such a system preferably is water. However, it can often be advantageous to use a mixed solvent system. Such a mixed solvent system is most preferably contains water mixed with aristotelem, particularly preferably in a mixture with a lower alcohol (for example, C1-6), in particular, ethanol and tert-butyl alcohol.

Preferred water systems include water in an amount constituting at least 25 wt.%, preferably, at least 35 wt.%. The upper limit of water content depends on the quantities of other �of ngredients, included in the composition, so that the water can make the rest of the substance up to 100% by weight of the composition.

The composition may further contain other components which are known to specialists in this field. Such components include, for example:

(a) humectants - ingredients that help maintain softness, smoothness and suppleness of the skin. Such ingredients may act through its ability to stay on the skin surface or in the stratum corneum to act as lubricants, to reduce or prevent peeling of the skin and improve its appearance. Examples of emollients include isopropyl myristate, triglycerides of fatty acids, for example, a triglyceride of lauric acid or a triglyceride of capric/Caprylic acids, such as triglyceride supplied for sale under the trade name Miglyol 810 (Huls UK) and a simple ether of propilenglikola and stearyl alcohol, known as stearyl ether PPF-15. Particularly preferred emollients include octyldodecanol and polysiloxane compounds, in particular compounds known as Dimethicone.

(b) a Wetting agent, or a humectants - ingredients that are designed to increase the water content in the upper layers of the skin. Examples of these ingredients are glycerin, sorbitol, 1,3-butyleneglycol and propylene glycol.

(c) Surfactants - surfactants can be used in the compositions according to the present invention as solubilization or cleaning agents or foam. For inclusion in the composition according to the present invention can suit a variety of different classes of surfactants known to specialists in this field, for which obvious their choice. Examples of suitable surfactants include anionic surfactants (e.g. sodium Laureth), nonionic surfactants (e.g., cocoglucoside), cationic surfactants and/or amphoteric surfactants (for example, cocamidopropylbetaine). These include polyethylene glycol ethers of alcohols, such as societally alcohol (e.g., isoceteth-20), isostearoyl alcohol (for example, isostearic-20), cetyl alcohol (for example, ceteth-20), alerby alcohol (e.g., will-20), Cetearyl alcohol (for example, cetearate-20).

(d) Preservatives - ingredients that prevent or delay microbial growth and, consequently, protect the composition from spoilage. Examples of preservatives include substances such as propylparaben, bronopol, dehydroacetic sodium, hydrochloride of polyhexamethyleneguanidine, isothiazole and diazolidinyl�Icewine.

(e) Helatoobrazovateli or complexing agents (chelators) - ingredients that have the ability to form complexes with metal ions and inactivate them, to prevent their adverse effects on the stability and appearance of the composition, as indicated above. Examples of complexing include ethylenediaminetetraacetic acid and its salts, preferably the dikalova, and particularly the disodium or tetrasodium salt.

(f) Abrasive materials - ingredients that contribute to the removal of unwanted tissue or foreign material from the skin during application of the composition. Abrasive materials usually contain small solid particles. Examples of suitable abrasive materials include plastic beads and aluminum oxide.

(g) cloud emulsions, such as clays (e.g. kaolin or bentonite), and titanium dioxide.

h) acidity Regulators - the ingredients used to control the pH of the composition. Examples of acidity regulators include inorganic compounds such as sodium hydroxide, and organic bases such as triethanolamine and arginine.

(i) Conditioning agents, for example, chloride distearyldimonium.

(j) the Flavors and dyes.

The composition according to the present invention can be applied to the skin and leave it on for achieving those desirable�piticescu effect or it can be applied to the skin and then wash it off for example, water in the case of compositions based on surfactants. The composition can be applied using a fibrous material, for example, a tampon or napkins.

According to another aspect of the present invention proposed article containing a fibrous substrate, for example, the material is in the form of a swab or wipes impregnated with a composition for skin care containing salicylic acid or its salt and at least two active ingredients selected from the group comprising lactic acid or its salt, glycyrrhizic acid or its salt or derivative, bisabolol, palmitate setinheritspopupmenu, allantoin, Niacinamide, and an extract of Epilobium angustifolium.

Fibrous material can be used for applying the composition to the skin.

Suitable fibrous materials include cellulose or cotton fibers, or a mixture thereof. Fibrous material can be impregnated with a composition, getting wet swab, which is designed for immediate application of the composition for skin care according to the present invention on the skin of the user. Alternatively, the fibrous material can be impregnated compositions for skin care and dried, yielding a dry tampon that before use it is necessary to moisten, for example, water.

According to another aspect of the present invention, p�idlogin method of prevention or remedial treatment of acne, where the specified method comprises local application to the skin of a patient of a composition for skin care containing salicylic acid or its salt, and at least two substances from the list that comprise lactic acid or its salt, glycyrrhizic acid or its salt and derivatives, bisabolol, palmitate of catalytically, allantoin, Niacinamide, and an extract of Epilobium angustifolium.

It should be noted that the method according to this aspect of the present invention can be a therapeutic method, but more often it is a mainly cosmetic method, the purpose of which is to reduce or eliminate visible and often unsightly manifestations of acne vulgaris.

In another aspect of the present invention is proposed to use salicylic acid and at least two active ingredients selected from the group comprising lactic acid (or its salts), glycyrrhizic acid (or its salts or derivatives), bisabolol, palmitate of catalytically, allantoin, Niacinamide, and an extract of Epilobium angustifolium, for the manufacture of a composition for the prevention or remedial treatment of acne by topical application of the composition on the skin.

Hereinafter the present invention will be described in more detail by the following examples, given merely as illust�tions.

Example 1: Serum

Example 2: Cleansing gel scrub

Example 3: mother-of-Pearl scrub-gel

Example 4: Lotion/mask

Example 5: Lotion/mask

Example 6: Aqueous-alcoholic gel

Example 7: scrub Cream

Example 8: Foamy cream scrub

The composition of each of these examples are fully described in the following tables 1-8.

Example 1

Example 2

Example 3

Example 4

Example 5

Example 6

Example 7

Example 8

Example 9

Example 10

Example 11. Test in vitro (skin model EpiDerm)

The purpose of this test in vitro was to evaluate the potential anti-inflammatory effect of the composition according to the present invention.

Tests in vitro were performed as follows:

- Used the model EpiDerm (TM) skin treated with the irritant agent. The initial inflammation was measured by the release of cytokines after application of a single dose of irritating the funds.

Have a dynamic range of studied compositions on the skin EpiDerm treated with the irritant agent.

- Then determined the anti-inflammatory potential to reduce secretions of cytokines.

In particular, evaluated the levels of cytokines TNF-α, IL-6 and IL-8, receiving data on the operation of the product throughout the development process acne or similar skin inflammation.

The experiment was planned according to standard procedures, using phorbol-12-myristate-13-acetate (PMA) as an irritant to the funds. The investigated samples in the form of a solution was applied by pipette onto the fabric EpiDerm and triple explored each sample in comparison with positive and negative control. Anti-inflammatory activity, as determined by a relative decrease in the excretion of cytokines in treated tissue irritant, compared with untreated tissue irritant. Researched individual active components for each of the examples according to the present invention together with certain combinations of them in pairs, where one combination did not include salicylic acid. The weight ratio insertion of active ingredients retained at the level of representative of the composition of example 9. The data in the table represent the values of the allocation of cytokines in PG/ml, where a lower value means a reduced level of excretion of cytokines, i.e. a lower degree of inflammation.

As you can see that salicylic acid works, including �AK anti-inflammatory agent, but unexpectedly, it also acts in combination with the ingredients of example according to the present invention, significantly reducing the inflammatory effect of each of these ingredients. This synergistic behavior is completely unexpected and allows you to make songs products according to the present invention, which, like tested, contain a wide variety of active ingredients for the treatment of lesions that occur at each stage of development of acne or similar skin inflammation.

1. Composition for skin care, suitable for topical application to the skin, where the specified composition comprises salicylic acid or its salt, in combination with:
- glycyrrhizic acid or its salt, or its derivative;
- palpitation of catalytically;
- lactic acid or its salt;
- bisabolol; and
- Niacinamide.

2. A composition according to claim 1, which contains salicylic acid.

3. A composition according to claim 2, in which the concentration of salicylic acid is at least 0.01 wt.%, preferably, at least 0.1 wt.%, most preferably at least 1 wt.%.

4. A composition according to claim 2, in which the concentration of salicylic acid is less than 10 wt.%, preferably less than 5 wt.% and most preferably less than 3 wt.%.

5. A composition according to claim 1, in which the con�entrace lactic acid or its salt is, at least 0.01 wt.%, preferably, at least 0.1 wt.% and most preferably at least 1 wt.%.

6. A composition according to claim 5, in which the concentration of lactic acid or its salt is less than 10 wt.%, preferably less than 5 wt.% and most preferably less than 3 wt.%.

7. A composition according to claim 1, in which the concentration of glycyrrhizic acid or its salt or derivative is at least 0.01 wt.%.

8. A composition according to claim 7, in which the concentration of glycyrrhizic acid or its salt or derivative is less than 2 wt.%, preferably less than 1 wt.% and most preferably less than 0.5 wt.%.

9. A composition according to claim 1, in which the concentration of bisabolol is at least 0.001 wt.%, preferably, at least 0.01 wt.% and most preferably at least 0.02 wt.%.

10. A composition according to claim 9, in which the concentration of bisabolol is less than 1 wt.%, preferably less than 0.5 wt.%.

11. A composition according to claim 1, in which the concentration of palmated of catalytically is at least 0.001 wt.%, preferably, at least 0.01 wt.%.

12. A composition according to claim 11, in which the concentration of palmated of catalytically is less than 1 wt.%, preferably less than 0.5 wt.%.

13. A composition according to claim 1, in which the concentration of Niacinamide is IU�Isha least 0.01 wt.%, preferably, at least 0.1 wt.% and most preferably at least 1 wt.%.

14. A composition according to claim 13, in which the concentration of Niacinamide is less than 10 wt.%, preferably less than 5 wt.%.

15. A composition according to claim 1, further comprising allantoin, in which the concentration of allantoin is at least 0.01 wt.%, preferably, at least 0.1 wt.% and most preferably at least 0.2 wt.%.

16. A composition according to claim 15, in which the concentration of allantoin is less than 5 wt.%, preferably less than 2 wt.% and most preferably less than 1 wt.%.

17. A composition according to claim 1, further comprising an extract of Epilobium angustifolium, in a concentration equal to at least 0.001 wt.%, preferably, at least 0.01 wt.%.

18. A composition according to claim 17, in which the concentration of an extract of Epilobium angustifolium is less than 1 wt.%, preferably less than 0.5 wt.%.

19. Composition for skin care according to any one of the preceding paragraphs, containing 0.1-5 wt.% salicylic acid or its salts in combination with:
- 0.1 to 5 wt.% lactic acid or its salts;
is 0.01 - 0.1 wt.% glycyrrhizic acid or its salt or derivative;
is 0.001-1 wt.% of bisabolol;
is 0.001-1 wt.% palmitate of catalytically; and
- 0.1 to 5 wt.% Niacinamide.

20. Composition for skin care according to claim 19, further contents�schaya:
- 0.1 to 2 wt.% allantoin; and
is 0.001-1 wt.% extract of Epilobium angustifolium.

21. Composition for skin care according to claim 21 containing from 1 to 3 wt.% salicylic acid or its salts in combination with at least two active ingredients selected from the group which consists of:
- 1-3 wt.% lactic acid or its salts;
is 0.01 - 0.5 wt.% glycyrrhizic acid or its salt, or a derivative;
- 0.02 to 0.5 wt.% of bisabolol;
is 0.01 - 0.5 wt.% palpitated of catalytically;
- 0.2 to 1 wt.% allantoin;
- 0.5 to 5 wt.% Niacinamide; and
is 0.01 - 0.5 wt.% extract of Epilobium angustifolium.

22. A composition according to claim 1 in which the pH is in the range from 3.5 to 6.0.

23. A composition according to claim 1, further comprising one or more other means for skin care, active when applied topically and is selected from antimicrobial or antibacterial compounds, antiviral compounds, antifungal compounds, anti-inflammatory compounds and antihelminthic compounds.

24. A composition according to claim 1, having the form of aqueous or oily lotion, dispersion, emulsion or gel containing a surfactant.

25. A composition according to claim 24, which has the form of an emulsion.

26. A composition according to claim 25, where the specified emulsion is an oil in water emulsion.

27. A composition according to claim 24, which is in the form of an aqueous gel.

28. To�position according to claim 1, which further comprises a gelling agent and/or thickener.

29. A composition according to claim 1, which contains a solvent system of water.

30. A composition according to claim 29, where the solvent system is a system of a mixture of solvents comprising water in combination with aristotelem.

31. A composition according to claim 30, in which Aristotel is an alcohol.

32. A composition according to claim 1, which contains one or more excipients selected from the group consisting of emulsifiers, emollients, lipids, wetting means or humectants, binders, conditioning means, stabilizing emulsion, salts, preservatives, helatoobrazovateli or complexing agents, abrasives, acidity regulators, surfactants, flavoring agents and dyes.

33. Article containing a fibrous substrate impregnated with the composition for skin care according to claim 1.

34. The product according to claim 33, containing cellulose or cotton fibers, or a mixture thereof.

35. Method of rehabilitation treatment of acne, which comprises local application to the skin of a patient of a composition for skin care according to claim 1.

36. A method according to claim 35, which is a cosmetic method.

37. A method according to claim 35, which is a therapeutic method.

38. Use of the composition according to claim 1 in to�notizie for rehabilitation treatment of acne by topical application of the composition on the skin.

39. A method for reducing irritation associated with the local application of the composition for skin care containing salicylic acid in combination with lactic acid or its salt, glycyrrhizic acid or its salt, or its derivatives, bisabolol, palpitation of catalytically and Niacinamide.

40. A method according to claim 39, where the composition additionally contains allantoin and extracts of Epilobium angustifolium.

41. A cosmetic method of improving the appearance of skin with acne damage, where the method includes reducing the redness from these lesions by topical application of the composition for skin care according to any of claims.1-32.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions concerns oral care compositions effective for treating dental hypersensitivity, and a method of treating using them. The composition contains a compound of formula I: M1-A-M2-B-M1; wherein M1 and M3 represent potassium (K); M2 represents Ti or titanium (Ti) oxide; A and B independently represent C2-C6 dibasic acid; and at least one orally acceptable solvent. The oral care composition has pH falling within the range of 2.0 to 7.0. There are also presented a version of the composition, which contains at least one additional desensitising agent, and a method of treating sensitive teeth with the use of this composition.

EFFECT: using the group of inventions provides the effective dental desensitisation by creating a protective barrier on the tooth surface and/or sealing the effective dental tubules effectively.

11 cl, 8 tbl, 12 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to the field of organic chemistry, namely to novel pyridine derivatives of the general formula

and to their pharmaceutically acceptable salts, where R1 stands for (C1-6) alkyloxy, CN or halogen, R2 stands for a hydrogen atom, R3 stands for a hydrogen atom or (C1-6) alkyl, R4, R5, R6, R7 are similar or different and stand for a hydrogen atom or halogen. The invention also relates to the cosmetic application of the formula (I) compound.

EFFECT: novel pyridine derivatives, useful in the treatment of diseases associated with a receptor of androgens, are obtained.

9 cl, 1 tbl, 16 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to health-promoting compositions and methods for preparing them. A method for preparing the composition of non-living lactic acid bacilli, possessing an ability of specific binding to Streptococcus mutans, involves the following stages: heating a cell suspension of lactic acid bacillus or a mixture of lactic acid bacilli possessing an ability of specific binding to Streptococcus mutans from an initial temperature of less than 40°C to a pasteurisation temperature of 75 to 85°C with a temperature variation within the range of 0.5 to 2°C/min, keeping the heated suspension at a pasteurisation temperature of 20 to 40 minutes and cooling the suspension to a final temperature of less than 40°C within the range of 0.5 to 2°C/min. The specific binding the cell suspension of the lactic acid bacillus or the mixture of lactic acid bacilli to Streptococcus mutans is stable to heat treatment and/or resistant to proteases and/or calcium-dependent and/or is observed within the range of pH values falling within the range of 4.5 and 8.5, and/or in the saliva environment.

EFFECT: invention enables producing the agent preventing or delaying the caries lesion formation.

9 cl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to cosmetic industry and represents a cosmetic product which has the following composition in each specific case calculated using the total composition: at least 0.1 wt % of at least one hydrophilic softening product, 2 to 40 wt % of at least one surfactant specified in a group of fatty alcohol ethoxylates, fatty alcohol ether sulphates and salts of sulphated and/or sulphonated fatty acids, 30 to 90 wt % of water, 1 to 30 wt % of one or more abrasives with the total ingredients making 10%; the product contains at least 0.1 wt % of at least one hydrophilic softening product with a hydrophilic-lipophilic balance ≥8 and flour thermally treated by saturated vapour; the flour is natural flour of shell or kernels characterized by a light absorption at wave length 660 nm of less than 1 prepared by reacting the flour 1 g with a solution prepared of water 10 ml and 0.1% aqueous methylene blue 1 ml.

EFFECT: invention provides the lower effect on viscosity, possesses the high cleaning action and high tolerability.

16 cl, 5 ex, 3 tbl

Foaming detergent // 2543713

FIELD: chemistry.

SUBSTANCE: invention relates to aqueous foaming composition for hands, containing castor oil maleate in amount from 0.1 to 1% of composition weight, PEG-7 glyceryl cocoate in amount from 0.05 to 0.3% of composition weight, glycerol in amount from 0.5 to 6% of composition weight, PEG-6 of glycerides of caprylic/capric acid in amount from 0.05 to 1% of composition weight and SAS. Glycerol is present in amount greater than amount of castor oil maleate or glyceryl cocoate PEG-7, and said composition has viscosity from 1 to 100 mPa·s (sP).

EFFECT: obtaining aqueous foaming composition for hands, which is capable of providing foam stability, has lower tendency for flowing and soiling when applied and creates more pleasant sensations for skin.

7 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to oral care compositions containing a basic amino acid or its salt. The presented oral care composition promoting the dentine defect closure in the oral cavity contains arginine in the free form or in the form of a salt, and an abrasive substance representing synthetic amorphous silica and containing small particle fractures making at least approximately 5% of total weight of the composition, wherein the particles of the small particle fracture having d50 from 3 to 4 mcm. What is also presented is a method of treating sensitive teeth in the oral cavity involving using the oral treatment with this composition, as well as using arginine as a part of the oral care composition and for producing a therapeutic agent, wherein the above composition and agent contain the above abrasive material containing the small particle fracture.

EFFECT: group of inventions provide the effective dentin defect closure in the patient's oral cavity.

8 cl, 1 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: rejuvenating effect is ensured by exposing high-molecular hyaluronic acid to gamma-radiation to preparing a stable low-molecular hyaluronic acid, which is used as a prescribed ingredient alongside with synthesised matrix peptide of specific amino acid sequence.

EFFECT: prescribed combination of low-molecular hyaluronic acid and matrix peptides of the developed cosmetic product enables achieving the pronounced aesthetic effect by a physiological mechanism of stimulation of developing proper hyaluronic acid in the skin.

2 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents an oral care composition, which contains 5 - 95 wt % of an orally acceptable carrier; and a film, wherein the above film contains 10 - 60 wt % of the film of an odour control active ingredient (a zinc-containing compound), 2 - 5 wt % of the film of a mucoadhesive polymer (polyacrylic acid or polyacrylate, polyalkylacrylate, polyvinylpyrrolidone, poly(acrylate)/polyvinylpyrrolidone copolymer, chitosan, 20 - 30 wt % of the film of one or more release controlling polymers (polyvinyl acetate or hydroxyethyl cellulose), 25 - 50 wt % of the film of a polymeric base (hydroxypropyl methyl cellulose, methyl cellulose, hydroxypropyl cellulose and a copolymer thereof) and a flavouring agent, wherein the above film is integrated into the above orally acceptable carrier and makes 0.1 - 5 wt % of the orally acceptable carrier.

EFFECT: invention provides creating the agent able to keep the breath fresh for a long period of time.

5 cl, 5 ex, 7 tbl, 6 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a foaming personal care composition containing: - a carrier; - an oil phase containing at least one terpene alcohol, which has a cyclic structure; - at least partially fluorinated compound; and - a stabilising agent, wherein the mass ratio of at least partially fluorinated compound and terpene alcohol makes from 2:1 to 4:1.

EFFECT: composition possesses higher stability and provides initial foaming and a longer positive skin effects, including cleansing and moistening.

16 cl, 12 tbl, 14 ex

Dry face mask // 2543355

FIELD: chemistry.

SUBSTANCE: invention represents a dry face mask containing a base, ground natural biologically active crude drugs, a natural abrasive, wherein the base is fermented malt, while the natural abrasive is ground dry rice having a particle size of 50-100 mcm; the mask ingredients are taken in certain relation, wt %.

EFFECT: invention enables reducing a possibility of skin injuries, promotes dynamic and age-related rhytid effacement, relieving skin inflammations and eliminating pigment spots.

4 cl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions concerns oral care compositions effective for treating dental hypersensitivity, and a method of treating using them. The composition contains a compound of formula I: M1-A-M2-B-M1; wherein M1 and M3 represent potassium (K); M2 represents Ti or titanium (Ti) oxide; A and B independently represent C2-C6 dibasic acid; and at least one orally acceptable solvent. The oral care composition has pH falling within the range of 2.0 to 7.0. There are also presented a version of the composition, which contains at least one additional desensitising agent, and a method of treating sensitive teeth with the use of this composition.

EFFECT: using the group of inventions provides the effective dental desensitisation by creating a protective barrier on the tooth surface and/or sealing the effective dental tubules effectively.

11 cl, 8 tbl, 12 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to the field of organic chemistry, namely to novel pyridine derivatives of the general formula

and to their pharmaceutically acceptable salts, where R1 stands for (C1-6) alkyloxy, CN or halogen, R2 stands for a hydrogen atom, R3 stands for a hydrogen atom or (C1-6) alkyl, R4, R5, R6, R7 are similar or different and stand for a hydrogen atom or halogen. The invention also relates to the cosmetic application of the formula (I) compound.

EFFECT: novel pyridine derivatives, useful in the treatment of diseases associated with a receptor of androgens, are obtained.

9 cl, 1 tbl, 16 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to health-promoting compositions and methods for preparing them. A method for preparing the composition of non-living lactic acid bacilli, possessing an ability of specific binding to Streptococcus mutans, involves the following stages: heating a cell suspension of lactic acid bacillus or a mixture of lactic acid bacilli possessing an ability of specific binding to Streptococcus mutans from an initial temperature of less than 40°C to a pasteurisation temperature of 75 to 85°C with a temperature variation within the range of 0.5 to 2°C/min, keeping the heated suspension at a pasteurisation temperature of 20 to 40 minutes and cooling the suspension to a final temperature of less than 40°C within the range of 0.5 to 2°C/min. The specific binding the cell suspension of the lactic acid bacillus or the mixture of lactic acid bacilli to Streptococcus mutans is stable to heat treatment and/or resistant to proteases and/or calcium-dependent and/or is observed within the range of pH values falling within the range of 4.5 and 8.5, and/or in the saliva environment.

EFFECT: invention enables producing the agent preventing or delaying the caries lesion formation.

9 cl, 4 ex

FIELD: medicine.

SUBSTANCE: 0.5% dihydroquercetin is instilled into the rectum of a patient with temporary colostomy until he/she starts feeling intestinal inflation. The procedure is performed twice a day, daily up until the restorative surgery.

EFFECT: method reduces a rate and a degree of colitis manifestations by the local antioxidant, anti-inflammatory effect, unfolding the excluded colon.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to cosmetic industry and represents a cosmetic product which has the following composition in each specific case calculated using the total composition: at least 0.1 wt % of at least one hydrophilic softening product, 2 to 40 wt % of at least one surfactant specified in a group of fatty alcohol ethoxylates, fatty alcohol ether sulphates and salts of sulphated and/or sulphonated fatty acids, 30 to 90 wt % of water, 1 to 30 wt % of one or more abrasives with the total ingredients making 10%; the product contains at least 0.1 wt % of at least one hydrophilic softening product with a hydrophilic-lipophilic balance ≥8 and flour thermally treated by saturated vapour; the flour is natural flour of shell or kernels characterized by a light absorption at wave length 660 nm of less than 1 prepared by reacting the flour 1 g with a solution prepared of water 10 ml and 0.1% aqueous methylene blue 1 ml.

EFFECT: invention provides the lower effect on viscosity, possesses the high cleaning action and high tolerability.

16 cl, 5 ex, 3 tbl

Foaming detergent // 2543713

FIELD: chemistry.

SUBSTANCE: invention relates to aqueous foaming composition for hands, containing castor oil maleate in amount from 0.1 to 1% of composition weight, PEG-7 glyceryl cocoate in amount from 0.05 to 0.3% of composition weight, glycerol in amount from 0.5 to 6% of composition weight, PEG-6 of glycerides of caprylic/capric acid in amount from 0.05 to 1% of composition weight and SAS. Glycerol is present in amount greater than amount of castor oil maleate or glyceryl cocoate PEG-7, and said composition has viscosity from 1 to 100 mPa·s (sP).

EFFECT: obtaining aqueous foaming composition for hands, which is capable of providing foam stability, has lower tendency for flowing and soiling when applied and creates more pleasant sensations for skin.

7 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to oral care compositions containing a basic amino acid or its salt. The presented oral care composition promoting the dentine defect closure in the oral cavity contains arginine in the free form or in the form of a salt, and an abrasive substance representing synthetic amorphous silica and containing small particle fractures making at least approximately 5% of total weight of the composition, wherein the particles of the small particle fracture having d50 from 3 to 4 mcm. What is also presented is a method of treating sensitive teeth in the oral cavity involving using the oral treatment with this composition, as well as using arginine as a part of the oral care composition and for producing a therapeutic agent, wherein the above composition and agent contain the above abrasive material containing the small particle fracture.

EFFECT: group of inventions provide the effective dentin defect closure in the patient's oral cavity.

8 cl, 1 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of producing technetium-99m labelled nanocolloid for radionuclide diagnosis. The disclosed method includes preparing a starting suspension of a nanocolloid in 0.1% sodium dodecylbenzene sulphate and passing said suspension through a filter with pore diameter of 100 nm, adding a technetium-99m eluate, then adding 0.20-0.25 mg ascorbic acid, 2.5-4.0 mg gelatine and 0.02-0.03 mg tin (II) chloride dihydrate per 1 ml of the mixture. The obtained mixture is heated in a water bath at 70-80°C for 30 minutes, cooled to room temperature in an ultrasonic bath and then subjected to sterilisation filtration. The nanocolloid used is iron-carbon particles whose surface is chemically modified with arenediazonium tosylate.

EFFECT: invention enables to obtain technetium-99m labelled nanocolloid, for which not less than 80% of particles have a size in the range of 20-100 nm, relative content of particles with a size smaller than 20 nm is not more than 6% and radiochemical purity is higher than 90% and is maintained for not less than 4 hours.

1 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: rejuvenating effect is ensured by exposing high-molecular hyaluronic acid to gamma-radiation to preparing a stable low-molecular hyaluronic acid, which is used as a prescribed ingredient alongside with synthesised matrix peptide of specific amino acid sequence.

EFFECT: prescribed combination of low-molecular hyaluronic acid and matrix peptides of the developed cosmetic product enables achieving the pronounced aesthetic effect by a physiological mechanism of stimulation of developing proper hyaluronic acid in the skin.

2 dwg, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents an oral care composition, which contains 5 - 95 wt % of an orally acceptable carrier; and a film, wherein the above film contains 10 - 60 wt % of the film of an odour control active ingredient (a zinc-containing compound), 2 - 5 wt % of the film of a mucoadhesive polymer (polyacrylic acid or polyacrylate, polyalkylacrylate, polyvinylpyrrolidone, poly(acrylate)/polyvinylpyrrolidone copolymer, chitosan, 20 - 30 wt % of the film of one or more release controlling polymers (polyvinyl acetate or hydroxyethyl cellulose), 25 - 50 wt % of the film of a polymeric base (hydroxypropyl methyl cellulose, methyl cellulose, hydroxypropyl cellulose and a copolymer thereof) and a flavouring agent, wherein the above film is integrated into the above orally acceptable carrier and makes 0.1 - 5 wt % of the orally acceptable carrier.

EFFECT: invention provides creating the agent able to keep the breath fresh for a long period of time.

5 cl, 5 ex, 7 tbl, 6 dwg

FIELD: medicine, oncology, amino acids.

SUBSTANCE: invention relates, in particular, to the development of an antitumor preparation based on natural substances. Invention relates to an amino acid preparation comprising at least one modified essential amino acid obtained by treatment of amino acid by ultraviolet radiation (UV) at wavelength 250-350 nm for 12-80 h at temperature 15-30oC or with ozone at temperature 15-25oC. The modified amino acid has no toxicity for health cells. Also, invention relates to a method for preparing such preparation. Invention provides the development of an antitumor preparation based on modified amino acids and expanded assortment of antitumor preparations being without cytotoxicity for normal cells.

EFFECT: valuable medicinal antitumor properties of preparation.

8 cl, 4 tbl, 2 dwg, 4 ex

Up!